Subscribe to Journal
Get full journal access for 1 year
only $102.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Quintás-Cardama A, Santos FPS, Garcia-Manero G. Therapy with azanucleosides for myelodysplastic syndromes. Oncogene. 2010;7:433–44.
Tsai H-C, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 2012;21:430–46.
Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell. 2015;162:974–86.
Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell. 2015;162:961–73.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–32.
Qin T, Jelinek J, Si J, Shu J, Issa J-PJ. Mechanisms of resistance to 5-aza-2’-deoxycytidine in human cancer cell lines. Blood. 2009;113:659–67.
Sripayap P, Nagai T, Uesawa M, Kobayashi H, Tsukahara T, Ohmine K, et al. Mechanisms of resistance to azacitidine in human leukemia cell lines. Exp Hematol. 2014;42:294–306.e2.
Valencia A, Masala E, Rossi A, Martino A, Sanna A, Buchi F, et al. Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. Leukemia. 2014;28:621–8.
Unnikrishnan A, Papaemmanuil E, Beck D, Deshpande NP, Verma A, Kumari A, et al. Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes. Cell Rep. 2017;20:572–85.
Cheng JX, Chen L, Li Y, Cloe A, Yue M, Wei J, et al. RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. Nat Commun. 2018;2018:1–16.
Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y, Richard N, et al. a comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS ONE. 2010;5:e9001.
Sebert M, Renneville A, Bally C, Peterlin P, Beyne-Rauzy O, Legros L, et al. A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. Haematologica. 2019;104:1565–71.
Roboz GJ, Döhner H, Gobbi M, Kropf PL, Mayer J, Krauter J, et al. Results from a global randomized phase 3 study of guadecitabine (G) vs treatment choice (TC) in 815 patients with treatment naïve (TN) AML unfit for intensive chemotherapy (IC) ASTRAL-1 study: analysis by Number of cycles. Blood. 2019;134:2591–1.
Issa JPJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O’Connell C, et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015;16:1099–110.
Gu X, Tohme R, Tomlinson B, Hasipek M, Durkin L, Schuerger C, et al. Resistance to decitabine and 5-azacytidine emerges from adaptive responses of the pyrimidine metabolism network. bioRxiv 2020.02.20.958405; https://doi.org/10.1101/2020.02.20.958405.
This work was supported by a grant in aid from the Cancer Council of Victoria to JS and LMK. LMK was supported by a fellowship from the Victorian Cancer Agency, JS was supported by a fellowship from the Australian Medical Research Future Fund, RWJ was supported by a fellowship from the National Health and Medical Research Council of Australia and EG was supported by the Australian Postgraduate Award.
Conflict of interest
The laboratory of JS has received research funding from Astex Pharmaceuticals. JS, LMK and RWJ served on the scientific advisory board of Celgene Corp.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Gruber, E., Franich, R.L., Shortt, J. et al. Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia. Leukemia (2020). https://doi.org/10.1038/s41375-020-0973-z